Thyroid associated ophthalmopathy.
DOI:
https://doi.org/10.20344/amp.1091Abstract
Thyroid associated ophthalmopathy is an uncommon disease, characterized by a diffuse inflammation of the orbit in a bilateral and asymmetric pattern, causing proptosis and swelling of the eyelids and conjuntiva. In 90% of the patients it is associated with Graves' disease, however it may occur with hipothyroidism or even without thyroid disease. During its course spontaneous remission or exacerbations are common, evolving independently from the thyroid disease, most often without serious complications for the patient, being blindness the worse of them, in 1% of the cases. The cause is still misunderstood but it is thought to be the result of an immune system disorder with the production of auto-antibodies directed against retro-bulbar fibroblasts and thyroid. Therapeutics is still a controversial matter. The balance between benefits and medication adverse effects is still to be made.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
